Table 4 Multivariable analysis of prognostic factors in locoregional advanced NPC
Endpoint | HR (95% CI) | p value* |
|---|---|---|
Local failure-free survival | ||
 Sex | 0.608 (0.201–1.844) | 0.380 |
 Age | 0.955 (0.311–2.937) | 0.936 |
 T stage | 0.733 (0.197–2.733) | 0.644 |
 N stage | 0.938 (0.114–7.738) | 0.953 |
 Induction chemotherapy | 1.321 (0.148–11.759) | 0.803 |
 Concurrent chemotherapy | >100 (0.000-..) | 0.988 |
 EBV DNA level | 0.089 (0.011–0.701) | 0.022 |
 Dose painting | 0.239 (0.061–0.932) | 0.039 |
Disease free survival | ||
 Sex | 1.504 (0.704–3.214) | 0.292 |
 Age | 1.261 (0.659–2.410) | 0.484 |
 T stage | 1.504 (0.704–3.214) | 0.513 |
 N stage | 1.261 (0.629–2.531) | 0.649 |
 Induction chemotherapy | 1.650 (0.524–5.197) | 0.392 |
 Concurrent chemotherapy | 0.659 (0.135–3.222) | 0.606 |
 EBV DNA level | 0.170 (0.069–1.417) | <0.001 |
 Dose painting | 0.462 (0.225–0.951) | 0.036 |
Distant metastasis-free survival | ||
 Sex | 3.334 (0.991–11.222) | 0.052 |
 Age | 1.697 (0.781–3.688) | 0.182 |
 T stage | 1.103 (0.471–2.581) | 0.821 |
 N stage | 0.688 (0.141–3.354) | 0.664 |
 Induction chemotherapy | 1.426 (0.298–6.829) | 0.657 |
 Concurrent chemotherapy | 0.640 (0.072–5.659) | 0.688 |
 EBV DNA level | 0.218 (0.079–0.601) | 0.003 |
 Dose painting | 0.453 (0.190–1.082) | 0.075 |
Overall survival | ||
 Sex | 1.456 (0.596–3.553) | 0.049 |
 Age | 1.166 (0.543–2.504) | 0.649 |
 T stage | 1.264 (0.558–2.860) | 0.575 |
 N stage | 0.264 (0.032–2.203) | 0.218 |
 Induction chemotherapy | 2.664 (0.794–8.937) | 0.113 |
 Concurrent chemotherapy | 0.328 (0.064–1.674) | 0.180 |
 EBV DNA level | 0.223 (0.082–0.607) | 0.003 |
 Dose painting | 0.425 (0.179–1.009) | 0.052 |